Literature DB >> 11522624

Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung.

S P Hussain1, P Amstad, K Raja, M Sawyer, L Hofseth, P G Shields, A Hewer, D H Phillips, D Ryberg, A Haugen, C C Harris.   

Abstract

p53 mutations are common in lung cancer. In smoking-associated lung cancer,the occurrence of G:C to T:A transversions at hotspot codons, e.g., 157, 248, 249,and 273, has been linked to the presence of carcinogenic chemicalsin tobacco smoke including polycyclic aromatic hydrocarbons suchas benzo(a)pyrene (BP). In the present study, we have used a highly sensitive mutation assay to determine the p53 mutation load in nontumorous human lung and to study the mutability of p53 codons 157, 248, 249, and 250 to benzo(a)pyrene-diol-epoxide (BPDE), an active metabolite of BP in human bronchial epithelial BEAS-2B cells. We determined the p53 mutational load at codons 157, 248, 249, and 250 in nontumorous peripheral lung tissue either from lung cancer cases among smokers or noncancer controls among smokers and nonsmokers. A 5-25-fold higher frequency of GTC(val) to TTC(phe) transversions at codon 157 was found in nontumorous samples (57%) from cancer cases (n = 14) when compared with noncancer controls (n = 8; P < 0.01). Fifty percent (7/14) of the nontumorous samples from lung cancer cases showed a high frequency of codon 249 AGG(arg) to AGT(ser) mutations (P < 0.02). Four of these seven samples with AGT(ser) mutations also showed a high frequency of codon 249 AGG(arg) to ATG(met) mutations, whereas only one sample showed a codon 250 CCC to ACC transversion. Tumor tissue from these lung cancer cases (38%) contained p53 mutations but were different from the above mutations found in the nontumorous pair. Noncancer control samples from smokers or nonsmokers did not contain any detectable mutations at codons 248, 249, or 250. BEAS-2B bronchial epithelial cells exposed to doses of 0.125, 0.5, and 1.0 microM BPDE, showed G:C to T:A transversions at codon 157 at a frequency of 3.5 x 10(-7), 4.4 x 10(-7), and 8.9 x 10(-7), respectively. No mutations at codon 157 were found in the DMSO-treated controls. These doses of BPDE induced higher frequencies, ranging from 4-12-fold, of G:C to T:A transversions at codon 248, G:C to T:A transversions and G:C to A:T transitions at codon 249, and C:G to T:A transitions at codon 250 when compared with the DMSO-treated controls. These data are consistent with the hypothesis that chemical carcinogens such as BP in cigarette smoke cause G:C to T:A transversions at p53 codons 157, 248, and 249 and that nontumorous lung tissues from smokers with lung cancer carry a high p53 mutational load at these codons.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522624

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy.

Authors:  Guang-Xia Chen; Li-Hong Zheng; Shi-Yu Liu; Xiao-Hua He
Journal:  World J Gastroenterol       Date:  2011-10-14       Impact factor: 5.742

2.  Comparison of p53 mutations induced by PAH o-quinones with those caused by anti-benzo[a]pyrene diol epoxide in vitro: role of reactive oxygen and biological selection.

Authors:  Yu-Min Shen; Andrea B Troxel; Srilakshmi Vedantam; Trevor M Penning; Jeffrey Field
Journal:  Chem Res Toxicol       Date:  2006-11       Impact factor: 3.739

Review 3.  Second-hand smoke and human lung cancer.

Authors:  Ahmad Besaratinia; Gerd P Pfeifer
Journal:  Lancet Oncol       Date:  2008-07       Impact factor: 41.316

Review 4.  Smoking, p53 mutation, and lung cancer.

Authors:  Don L Gibbons; Lauren A Byers; Jonathan M Kurie
Journal:  Mol Cancer Res       Date:  2014-01       Impact factor: 5.852

Review 5.  Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression.

Authors:  Rita Nahta; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Rafaela Andrade-Vieira; Sarah N Bay; Dustin G Brown; Gloria M Calaf; Robert C Castellino; Karine A Cohen-Solal; Annamaria Colacci; Nichola Cruickshanks; Paul Dent; Riccardo Di Fiore; Stefano Forte; Gary S Goldberg; Roslida A Hamid; Harini Krishnan; Dale W Laird; Ahmed Lasfar; Paola A Marignani; Lorenzo Memeo; Chiara Mondello; Christian C Naus; Richard Ponce-Cusi; Jayadev Raju; Debasish Roy; Rabindra Roy; Elizabeth P Ryan; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Renza Vento; Jan Vondráček; Mark Wade; Jordan Woodrick; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

Review 6.  Lung cancer. 9: Molecular biology of lung cancer: clinical implications.

Authors:  K M Fong; Y Sekido; A F Gazdar; J D Minna
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

7.  An association between BPDE-like DNA adduct levels and CYP1A1 and GSTM1 polymorphisma in pterygium.

Authors:  Jai-Nien Tung; Heng-Hsiung Wu; Chun-Chi Chiang; Yi-Yu Tsai; Ming-Chih Chou; Huei Lee; Ya-Wen Cheng
Journal:  Mol Vis       Date:  2010-04-08       Impact factor: 2.367

8.  CYP1A1 gene polymorphisms as a risk factor for pterygium.

Authors:  Chi-Hsien Young; Yu-Lun Lo; Yi-Yu Tsai; Tung-Sheng Shih; Huei Lee; Ya-Wen Cheng
Journal:  Mol Vis       Date:  2010-06-09       Impact factor: 2.367

Review 9.  Clinical Outcomes of TP53 Mutations in Cancers.

Authors:  Ana I Robles; Jin Jen; Curtis C Harris
Journal:  Cold Spring Harb Perspect Med       Date:  2016-09-01       Impact factor: 6.915

Review 10.  Lung cancer biology: a genetic and genomic perspective.

Authors:  M Sánchez-Céspedes
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.